Dendritic cell immunotherapy for cancer: Application to low-grade lymphoma and multiple myeloma

Immunology and Cell Biology

Volumn 77, Issue 5, 1999, Pages 451-459

  Hart, D N J ^a   Hill, G R ^a  

^a MATER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Dendritic cells; Idiotype; Immunotherapy; Low grade non Hodgkin's lymphoma; Multiple myeloma

Indexed keywords

AMINO ACID; TUMOR ANTIGEN;

ANTIGEN PRESENTING CELL; DENDRITIC CELL; IMMUNE RESPONSE; IMMUNOTHERAPY; LYMPHOMA; MAJOR HISTOCOMPATIBILITY COMPLEX; MULTIPLE MYELOMA; REVIEW; T LYMPHOCYTE;

ANIMALS; ANTIGENS, NEOPLASM; CELL COUNT; CELL DIFFERENTIATION; CELLS, CULTURED; DENDRITIC CELLS; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN IDIOTYPES; IMMUNOTHERAPY; LYMPHOMA, LOW-GRADE; MULTIPLE MYELOMA; NEOPLASMS;

ANIMALIA;

EID: 0032830110     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1711.1999.00859.x     Document Type: Review

References (99)

1. 1 Frayer I. Strategies for immunoprophylaxis and immunotherapy of papilloma viruses. Clin. Dermatol. 1997; 15: 285-97.
2. 2 Moss DJ, Suhrbier A, Elliot SL. Candidate vaccines for Epstein Barr Virus. BMJ 1998; 317: 423-4.
3. + T lymphocytes respond to dendritic cells pulsed with b3a2 peptide and antigen-presenting cells exposed to b3a2 containing cell lysates. Blood 1997; 90: 290-7.
4. 4 Gedde-Dahl T, Fossum B, Eriksen JA, Thorsby E, Gaudernack G. T cell clones specific for p21 ras-derived peptides; Characterization of their fine specificity and HLA restriction. Eur. J. Immunol. 1993; 23: 754-60.
5. 5 Ellem KAO, Schmidt CW, O'Rourke MGE et al. The labyrinthine ways of cancer immunotherapy - T cell, tumour cell encounter. 'How do I lose thee? Let me count the ways?' Adv. Canc. Res. 1998; 75: 203-49.
6. 6 Cross NC, Hughes TP, Feng L et al. Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: Correlations with acute graft-versus-host disease and relapse. Br. J. Haematol. 1993; 84: 67-74.
7. 7 Kolb H, Schattenberg A, Goldman J, Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041-50.
8. 8 Hart DNJ. Dendritic cells: Unique leucocyte populations which control the primary immune response. Blood 1997; 90: 3245-87.
9. 9 McLellan AD, Heiser A, Sorg RV, Fearnley DB, Hart DNJ. Dermal dendritic cells associated with T lymphocytes in normal human skin display an activated phenotype. J. Invest. Dermatol. 1998; 111: 841-9.
10. + hematopoietic progenitor cells. Blood 1996; 87: 1292-302.
11. 11 Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumour necrosis factor α. J. Exp. Med. 1994; 179: 1109-18.
12. + monocyte derived dendritic cells: Insights into phenotype and function. Exp. Hematol. 1998; 26: 1255-64.
13. 13 Shortman K, Wu L, Ardavin C et al. Thymic dendritic cells; surface phenotype, developmental origin and function. Adv. Exp. Med. Biol. 1995; 378: 21-9.
14. 14 Maraskovsky E, Brasel K, Teepe M et al. Dramatic increase in the numbers of functionally mature dendritic cells in FIt3 ligand-treated mice: Multiple dendritic cell subpopulations identified. J. Exp. Med. 1996; 184: 1953-62.
15. 15 Galy A, Travis M, Cen D, Chen B, Human T, B, natural killer and dendritic cells arise from a common bone marrow progenitor cell subset. Immunity 1995; 3: 459-73.
16. 16 Res. P, Martinezcaceres E, Jaleco AC et al. CD34 (+) CD38 (dim) cells in the human thymus can differentiate into T, natural killer, and dendritic cells but are distinct from pluripotent stem cells. Blood 1996; 87: 5196-206.
17. 17 Olweus J, BitMansour A, Warnke R et al. Dendritic cell ontogeny: A human dendritic cell lineage of myeloid origin. Proc. Natl Acad. Sci. USA 1997; 94: 12551-6.
18. 18 O'Doherty U, Peng M, Gezelter S et al. Human blood contained two subsets of dendritic cells, one immunologically mature and the other immature. Immunology 1994; 82: 487-93.
19. 19 Grouard G, Clark EA. Role of dendritic cells and follicular dendritic cells in HIV infection and pathogenesis. Curr. Opin Immunol. 1997; 9: 563-7.
20. 20 Grouard G, Rissoan M-C, Filgueira L, Durand I, Banchereau J, Liu Y-J. The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL) -3 and CD40-ligand. J. Exp. Med. 1997; 185: 1101-11.
21. 21 Grouard G, Durand I, Filgueira L, Banchereau J, Liu Y-J. Dendritic cells capable of stimulating T cells in germinal centres. Nature 1996; 384: 364-7.
22. 22 Zhou L, Schwarling R, Smith HM, Tedder TF. A novel cell-surface molecule expressed by human interdigitating reticulum cells, Langerhans cells, and activated lymphocytes is a new member of the Ig superfamily. J. Immunol. 1992; 149: 735-42.
23. 23 Hock BD, Starling GC, Daniel PB, Hart DNJ. Characterisation of CMRF-44, a novel monoclonal antibody to an activation antigen expressed by the allostimulatory cells within peripheral blood, including dendritic cells. Immunology 1994; 83: 573-81.
24. 24 Fearnley DB, McLellan AD, Mannering SI, Hock BD, Hart DNJ. Isolation of human blood dendritic cells using the CMRF-44 monoclonal antibody: Implications for studies on antigen presenting cell function and immunotherapy. Blood 1997; 89: 3708-16.
25. 25 Hock BD, Fearnley DB, Boyce A et al. Human dendritic cells express a 95kDa activation/differentiation antigen defined by CMRF-56. Tissue Antigens 1999; 53: 320-34.
26. 26 Clark GJ, Gunningham SP, Troy AJ, Vuckovic S, Hart DNJ. Expression of the RelB transcription factor correlates with the activation of human dendritic cells. Immunology 1999; in press.
27. 27 de Saint-Vis B, Vincent J, Vandenabeele S et al. A novel lysosome-associated membrane glycoprotein, DC-LAMP, induced upon DC maturation, is transiently expressed in MHC Class II compartment. Immunity 1998; 9: 325-36.
28. 28 Kato M, Neil T, Clark G, Morris C, Sorg R, Hart DNJ. cDNA cloning of human DEC-205, a putative antigen-uptake receptor on dendritic cells. Immunogenetics 1998; 47: 442-50.
29. 29 Mannering SI, McKenzie JL, Hart DNJ. Optimisation of the conditions for generating human DC initiated primary antigen specific T lymphocyte lines in vitro. J. Immunol. Meth. 1998; 219: 69-83.
30. 30 Fernandez NC, Lozier A, Flament C et al. Dendritic cells directly trigger NK cell functions: Cross-talk relevant in innate anti-tumor immune responses in vivo. Nat. Med. 1999; 5: 405-11.
31. 31 Geldhof AB, Moser M, Lespagnard L, Thielemans K, De Baetselier P. Interleukin-12-activated natural killer cells recognize B7 costimulatory molecules on tumor cells and autologous dendritic cells. Blood 1998; 91: 196-206.
32. 32 Adema GJ, Hartgers F, Verstraten R et al. A dendritic-cell-derived C-C chemokine that preferentially attracts naive T cells. Nature 1997; 387: 713-17.
33. 33 Chan VWF, Kothakota S, Rohan MC et al. Secondary lymphoid-tissue chemokine (SLC) is chemotactic for mature dendritic cells. Blood 1999; 93: 3610-16.
34. 34 McLellan AD, Sorg RV, Williams LA, Hart DNJ. Human dendritic cells activate T lymphocytes via a CD40:CD40 ligand-dependent pathway. Eur. J. Immunol. 1996; 26: 1204-10.
35. 35 McLellan AD, Heiser A, Hart DNJ. Induction of dendritic cell costimulator molecule expression is suppressed by T cells in the absence of antigen specific signalling: Role of cluster formation, CD40 and HLA-class II for DC activation. Immunology 1999; in press.
36. 36 Steinbrink K, Wolfl M, Jonuleit H, Knop J, Enk A. Induction of tolerance by interleukin-10 -treated dendritic cells. J. Immunol. 1997; 159: 4772-80.
37. 37 Steinbrink K, Jonuleit H, Muller G, Schuler G, Knop J, Enk A. Interleukin-10 treated human dendritic cells induce a melanoma antigen-specific anergy in CD8+ T cells resulting in a failure to lyse tumor cells. Blood 1999; 93: 1634-42.
38. 38 Rissoan M, Soumelis V, Kaduwaki N et al. Reciprocal control of T helper cell and dendritic cell differentiation. Science 1999; 283: 1183-6.
39. 39 Pulendran B, Smith J, Caspary G et al. Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc. Natl Acad. Sci. USA 1999; 96: 1036-41.
40. 40 Gabrilovich DI, Corak J, Ciernik IF, Kavanaugh D, Carbone DP. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin. Canc. Res. 1997; 3: 483-90.
41. 41 Troy AJ, Summers KL, Davidson PJT, Atkinson CA, Hart DNJ. Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin. Canc. Res. 1998; 4: 585-93.
42. 42 Troy AJ, Davidson P, Atkinson C, Hart D. Phenotypic characterization of the dendritic cell infiltrate in prostate cancer. J. Urol. 1998; 160: 214-19.
43. 43 Troy AJ, Davidson PJT, Atkinson CH, Hart DNJ. CD1a dendritic cells predominate in transitional cell carcinoma of bladder and kidney but are minimally activated. J. Urol. 1999; 161: 1962-7.
44. 44 Troy AJ, Hart DNJ. Dendritic cells in cancer: Progress towards a new cellular therapy. J. Hematother. 1997; 6: 523-33.
45. 45 Summers KL, O'Donnell JL, Highton J, Hart DNJ. Chronic arthritic synovial fluid TGF-β inhibits dendritic cell-T lymphocyte interactions. Arth. Rheum. 1999; 42: 507-18.
46. 46 Vuckovic S, Fearnley DB, Gunningham SP, Spearing RL, Patton WN, Hart DNJ. Dendritic cells in chronic myelomonocytic leukaemia. Br. J. Haematol. 1999; 105: 974-85.
47. 47 Gabrilovich DI, Nadaf S, Corak J, Berzofsky JA, Carbone DP. Dendritic cells in antitumor immune responses. Cell Immunol. 1996; 170: 111-19.
48. 48 Fearnley DB, Whyte LF, Carnoutsos SA, Cook AH, Hart DNJ. Monitoring human blood dendritic cell numbers in normal individuals and in stem cell transplantation. Blood 1998; 93: 728-36.
49. 49 Brown R, Pope B, Gibson J, Hart D, Joshua D. Dendritic cells and plasma cells from patients with myeloma as antigen presenting cells. Blood 1998; 92: A716.
50. 50 Stevenson F, Link C, Traynor A, Yu H, Corr M. DNA vaccination against multiple myeloma. Semin. Hematol. 1999; 36: 38-42.
51. 51 Dranoff G, Jaffee E, Lazenby A et al. Vaccination with irradiated tumour cells engineered to secrete murine granulocyte-macrophage colony stimulating factor stimulates potent, specific and lasting anti-tumour immunity. Proc. Natl Acad. Sci. USA 1993; 90: 3539-43.
52. 52 Romani N, Reider D, Heuer M et al. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicabililty. J. Immunol. Meth. 1996; 196: 137-51.
53. 53 Bender A, Sapp M, Schuler G, Steinman RM, Bhardwaj N. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J. Immunol Math. 1996; 196: 121-35.
54. 54 Nestle FO, Gilliet M, Alljagic S et al. Vaccination of melanoma patients with peptide-pulsed dendritic cells. Melanoma Res. 1997; 7: S14.
55. 55 Murphy GP, Tjoa BA, Simmons SJ et al. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase 2 prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate 1999; 38: 73-8.
56. 56 Nestle FO, Zheng X-G, Thompson CB, Turka LA, Nickoloff BJ. Characterization of dermal dendritic cells obtained from normal human skin reveals phenotypic and functionally distinctive subsets. J. Immunol. 1993; 151: 6535-45.
57. + blood progenitors for anticancer therapy. Exp. Hematol. 1995; 23: 1463-71.
58. 58 Hsu FJ, Benike C, Fagnoni F et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 1996; 2: 52-7.
59. 59 Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 1996; 29: 371-80.
60. 60 Labeur M, Roters B, Pers B et al. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J. Immunol. 1999; 162: 168-75.
61. 61 Morse M, Lyerly H, Gilboa E, Thomas E, Nair S. Optimization of the sequence of antigen loading and CD40-ligand induced maturation of dendritic cells. Canc. Res. 1998; 58: 2965-8.
62. 62 Ronchetti A, Rovere P, Iezzi G et al. Immunogeneicity of apoptotic cells in vivo; Role of antigen load, antigen-presenting cells, and cytokines. J. Immunol. 1999; 163: 130-6.
63. 63 Tamada K, Harada M, Abe K et al. Antitumor vaccination effect of dendritic cells can be augmented by locally utilizing Th1-type cytokines from OK432-reactive CD4+ T cells. Cancer Immunol. Immunother. 1998; 46: 128-36.
64. 64 Ogata M, Zhang Y, Wang Y et al. Chemotactic response toward chemokines and its regulation by transforming growth factor-beta1 of murine bone marrow hematopoietic progenitor cell derived different subset of dendritic cells. Blood 1999; 93: 3225-32.
65. 65 Barratt-Boyes SM, Watkins SC, Finn OJ. In vivo migration of dendritic cells differentiated in vitro. J. Immunol. 1997; 158: 4543-7.
66. 66 Morse M, Coleman R, Akabani G, Niehaus N, Coleman D, Lyerly H. Migration of human dendritic cells after injection in patients with metastatic malignancies. Canc. Res. 1999; 59: 56-8.
67. 67 Morikawa Y, Tohya K, Ishida H, Matsuura N, Kakudo K. Different migration patterns of antigen-presenting cells correlate with Th1/Th2-type responses in mice. Immunology 1995; 85: 575-81.
68. 68 Dillon SM, Griffin JFT, Hart DNJ, Watson JD, Baird MA. A long-lasting IFN-alpha response is induced to a single inoculation of antigen-pulsed dendritic cells. Immunol. 1998; 95: 132-40.
69. 69 Zitvogel L, Regnault A, Lozier A et al. Eradication of established murine tumors using a novel cell-free vaccine: Dendritic cell-derived exosomes. Nat. Med. 1998; 4: 594-600.
70. 70 Reichardt V, Okada C, Liso A et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - A feasibility study. Blood 1999; 93: 2411-19.
71. 71 Gribben JG, Freedman AS, Neuberg D. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N. Engl. J. Med. 1991; 325: 1525-33.
72. 72 McLaughlin P, Grillo-Lopez AJ, Link BK. et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J. Clin. Oncol. 1998; 16: 2825-33.
73. 73 Kaminski MS, Zasadny KR, Francis IR et al. Radio-immunotherapy of B-cell lymphoma with anti-B1 (anti-CD20) antibody. N. Engl. J. Med. 1993; 329: 459-65.
74. 74 Ratanatharathorn V, Uberti J, Karanes C. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood 1994; 84: 1050-55.
75. 75 Jones RJ, Ambinder RF, Piantadosi S. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991; 77: 649-53.
76. 76 Appelbaum FR, Sullivan KM, Buckner CD. Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation and marrow transplantation. J. Clin. Oncol 1987; 5: 1340-47.
77. 77 Miller RA, Maloney DG, Warnke R, Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N. Engl. J. Med. 1982; 306: 517-22.
78. 78 Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N. Engl. J. Med. 1992; 327: 1209-15.
79. 79 Hawkins RE, Zhu D, Ovecka M, Winer G, Hamblin TJ, Stevenson FK. Idiotypic vaccination against B-cell lymphoma: Rescue of variable region gene sequences from biopsy material for assembly as single chain Fv 'personal' vaccines. Blood 1994; 83: 3279-88.
80. 80 Flamand V, Sornasse T, Thielemans K et al. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur. J. Immunol. 1994; 24: 605-10.
81. 81 Hawkins RE, Zhu D, Ovecka M et al. Idiotypic vaccination against B-cell lymphoma. Rescue of variable region gene sequences from biopsy material for assembly as single chain. Fv personal vaccines. Blood 1994; 83: 3279-88.
82. 82 King C, Spellerberg M, Zhu D et al. DNA vaccines with single chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat. Med. 1998; 4: 1281-6.
83. 83 Joshua DE, Myeloma: New aspects of biology, prognosis and treatment. Pathology 1996; 28: 2-7.
84. 84 Anderson K, Hamblin T, Traynor A. Management of multiple myeloma today. Semin. Hematol. 1999; 36: 3-8.
85. 85 Blade J, Samson D, Reece D et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high dose therapy and haemopoietic stemcell transplantation. Myeloma subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Bone Marrow Transplant 1998; 21: 133-40.
86. 86 Tricot G, Vestole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-versus-myeloma effect: Proof of principle. Blood 1996; 87: 1196-8.
87. 87 Kwak LW, Taub DD, Duffey DL et al. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 1995; 345: 1016-20.
88. 88 Osterborg A, Yi Q, Henriksson L et al. Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type1, major histocompatibility complex-restricted, Cd8-and Cd4-specific T cell responses. Blood 1998; 91; 2549-66.
89. 89 Wen Y, Ling M, Bailey-Wood R, Lim S. Idiotype protein pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma. Clin. Canc. Res. 1998; 4: 957-62.
90. 90 Dabadghao S, Bergenbrant S, Anton D, He W, Holm G, Yi Q. Anti-idiotypic T cell activation in multiple myeloma induced by M-component fragments presented by dendritic cells. Br. J. Haematol. 1998; 100: 647-54.
91. 91 Yi Q, Osterborg A, Bergenbrant S, Mellstedt H, Holm G, Lefvert AK. Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies. Blood 1995; 86: 3043-9.
92. 92 Brown RD, Yuen E, Nelson M, Gibson J, Joshua D. The prognostic significance of T cell receptor beta gene rearrangements and idiotype-reactive T cells in multiple myeloma. Leukemia 1997; 11: 1312-17.
93. 93 Turner J, Tan J, Crucian B et al. Broadened utility of gene gunmediated, granulocyte colony-stimulating factor cDNA-based tumor cell vaccines as demonstrated with a mouse myeloma model. Hum. Gene Ther. 1998; 9: 1121-30.
94. 94 Tarte K, Olsen SJ, Yang Lu Z et al. Clinical-grade functional dendritic cells from patients with multiple myeloma are not infected with Kaposi's sarcoma-associated herpesvirus. Blood 1998; 91; 1852-7.
95. 95 Cull GM, Timms JM, Haynes AP et al. Dendritic cells cultured from mononuclear cells and CD34 cells in myeloma do not harbour human herpesvirus 8. Br. J. Haematol. 1998; 100: 793-6.
96. 96 Pfeiffer S, Gooding RP, Apperley JF, Goldschmidt H, Samson D. Dendritic cells generated from the blood of patients with multiple myeloma are phenotypically and functionally identical to those similarly produced from healthy donors. Br. J. Haematol. 1997; 98: 973-82.
97. 97 Cull G, Durrant L, Haynes A, Russell N. Generation of idiotype-specific immune responses following vaccination with autologous paraprotein pulsed dendritic cells in myeloma. Blood 1998; 92: 275b.
98. 98 Choi D, Perrin M, Hoffmann S et al. Dendritic cell-based vaccines in the setting of peripheral blood stem cell transplantation; CD34+ cell-depleted mobilized peripheral blood can serve as a source of potent dendritic cells. Clin. Canc. Res. 1998; 4: 2709-16.
99. 99 Brisco M, Tan L, Orsborn A, Morley A. Development of a highly sensitive assay, based on the polymerase chain reaction, for rare B-lymphocyte clones in a polyclonal population. Br. J. Haematol. 1990; 75: 163-7.